Iovance Biotherapeutics, Inc. IOVA Change in AR
Change in AR at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s change in ar.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s change in AR?
- Iovance Biotherapeutics, Inc. (IOVA) reported change in AR of -$690K in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s change in AR changed year-over-year?
- Iovance Biotherapeutics, Inc.'s change in AR decreased by 143.2% year-over-year, from $1.6M to -$690K.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s change in AR?
- Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s change in AR has grown at a 837.9% compound annual growth rate (CAGR), from $149K to $13.11M.
- What does change in AR mean?
- Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.